









市场行情
/
股票
/
nasdaq-fbio
/

Fortress Biotech Inc

FBIO

3.540USD

+0.220+6.63%

收盘 12/19, 16:00（美东）报价延迟15分钟

109.76M总市值

亏损市盈率 TTM



Fortress Biotech Inc

3.540

+0.220+6.63%

概览公司财务分析

概览

公司

财务

分析

关于 Fortress Biotech Inc 公司

Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.

Fortress Biotech Inc简介



公司代码FBIO

公司名称Fortress Biotech Inc

上市日期Nov 17, 2011

CEORosenwald (Lindsay A)

员工数量101

证券类型Ordinary Share

年结日Nov 17

公司地址1111 Kane Concourse

城市BAY HARBOR ISLANDS

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编33154

电话17816524500

网址https://www.fortressbiotech.com/

公司代码FBIO

上市日期Nov 17, 2011

CEORosenwald (Lindsay A)

Fortress Biotech Inc公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Lindsay A. Rosenwald, M.D.

Executive Chairman of the Board, President, Chief Executive Officer

4.11M

-27.60%

Mr. Michael S. Weiss, J.D.

Executive Vice Chairman - Strategic Development, Director

1.80M

Mr. Dov Klein, CPA

Independent Director

27.44K

Mr. David Jin

Chief Financial Officer and Head of Corporate Development

13.60K

+24.89%

Dr. Lucy Lu, M.D.

Chief Strategy Officer

5.22K

Mr. J. Jay Lobell, J.D.

Independent Director

Mr. Malcolm I. Hoenlein, Ph.D.

Independent Director

Dr. Jimmie Harvey, Jr., M.D.

Independent Director

Ms. Jaclyn Jaffe

Investor Relations

Mr. Kevin L. Lorenz, J.D.

Independent Director

名称

名称/职务

职务

持股

持股变动

Dr. Lindsay A. Rosenwald, M.D.

Executive Chairman of the Board, President, Chief Executive Officer

4.11M

-27.60%

Mr. Michael S. Weiss, J.D.

Executive Vice Chairman - Strategic Development, Director

1.80M

Mr. Dov Klein, CPA

Independent Director

27.44K

Mr. David Jin

Chief Financial Officer and Head of Corporate Development

13.60K

+24.89%

Dr. Lucy Lu, M.D.

Chief Strategy Officer

5.22K

Mr. J. Jay Lobell, J.D.

Independent Director

收入明细

单位: USD更新时间: 4月2日周三

FY2023

FY2023Q4

FY2022

FY2022Q4

FY2021

FY2019

业务USD

名称

营收

占比

Targadox®

3.20M

3.79%

Exelderm®

2.40M

2.83%

Ximino®

287.00K

0.34%

由于公司未披露，未能获取相关数据

业务

地区

业务USD

名称

营收

占比

Targadox®

3.20M

3.79%

Exelderm®

2.40M

2.83%

Ximino®

287.00K

0.34%

股东统计

更新时间: 11月17日周一

持股股东

股东类型

持股股东

占比

Rosenwald (Lindsay A)

13.25%

Weiss (Michael S)

5.80%

The Vanguard Group, Inc.

3.06%

Summit Financial, LLC

1.43%

Susquehanna International Group, LLP

1.15%

其他

75.31%

持股股东

占比

Rosenwald (Lindsay A)

13.25%

Weiss (Michael S)

5.80%

The Vanguard Group, Inc.

3.06%

Summit Financial, LLC

1.43%

Susquehanna International Group, LLP

1.15%

其他

75.31%

股东类型

持股股东

占比

Individual Investor

20.12%

Investment Advisor

10.59%

Investment Advisor/Hedge Fund

2.69%

Hedge Fund

1.26%

Research Firm

0.51%

Bank and Trust

0.09%

Pension Fund

0.06%

其他

64.69%

机构持股



更新时间: 12月8日周一

报告期

机构数

持股数

持股占比

持股变动

2025Q4

4.96M

26.50%

2025Q3

107

4.96M

27.33%

2025Q2

114

4.96M

27.45%

+47.82K

2025Q1

116

4.91M

27.75%

-3.29M

2024Q4

121

4.82M

26.63%

+370.47K

2024Q3

123

4.48M

24.67%

+822.95K

2024Q2

130

3.66M

27.39%

+620.10K

2024Q1

155

3.04M

28.91%

-2.56M

2023Q4

162

4.72M

15.96%

+3.18M

2023Q3

164

1.59M

428.37%

-108.10K

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Rosenwald (Lindsay A)

4.11M

13.82%

-1.57M

-27.60%

Apr 17, 2025

Weiss (Michael S)

1.80M

6.05%

Apr 17, 2025

The Vanguard Group, Inc.

852.92K

2.87%

+100.37K

+13.34%

Jun 30, 2025

Summit Financial, LLC

1.02M

3.41%

+1.02M

Jun 30, 2025

PVG Asset Management Corporation

321.96K

1.08%

-150.26K

-31.82%

Jun 30, 2025

Shikiar Asset Management, Inc.

278.47K

0.94%

+42.50K

+18.01%

Jun 30, 2025

Geode Capital Management, L.L.C.

234.79K

0.79%

-2.74K

-1.16%

Jun 30, 2025

Northern Trust Investments, Inc.

93.22K

0.31%

+57.31K

+159.61%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

iShares Micro-Cap ETF

0.01%

Fidelity Enhanced Small Cap ETF

iShares Micro-Cap ETF

占比0.01%

Fidelity Enhanced Small Cap ETF

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

Oct 09, 2023

Merger

15→1

Oct 09, 2023

Merger

15→1

Oct 09, 2023

Merger

15→1

Oct 09, 2023

Merger

15→1

公告日期

类型

比率

Oct 09, 2023

Merger

15→1

Oct 09, 2023

Merger

15→1

Oct 09, 2023

Merger

15→1

Oct 09, 2023

Merger

15→1

常见问题

Fortress Biotech Inc的前五大股东是谁？



Fortress Biotech Inc 的前五大股东如下：
Rosenwald (Lindsay A)持有股份：4.11M，占总股份比例：13.82%。
Weiss (Michael S)持有股份：1.80M，占总股份比例：6.05%。
The Vanguard Group, Inc.持有股份：852.92K，占总股份比例：2.87%。
Summit Financial, LLC持有股份：1.02M，占总股份比例：3.41%。
PVG Asset Management Corporation持有股份：321.96K，占总股份比例：1.08%。